New York, May 22, 2026, 4:02 PM EDT
- BioAge Labs lost 0.8% at $16.61 on Friday, lagging the Nasdaq Composite, which was stronger.
- BioAge Labs said its CFO and chief strategy officer are set to appear at the Jefferies Global Healthcare Conference on June 4.
- BGE-102, an oral NLRP3 inhibitor, is still in focus for investors. BioAge Labs plans to kick off two proof-of-concept trials around mid-2026.
BioAge Labs shares ended lower Friday, giving up 0.8% to close at $16.61. The move trailed the Nasdaq Composite, which Reuters said was up 0.5% in the afternoon. The clinical-stage biotech set new investor meetings for June but didn’t provide clinical updates.
BioAge put out a standard notice, but the timing caught investors. The company is moving toward a period where investors need results from BGE-102, its main drug, as it shifts from early biomarker numbers to key patient trials in heart and retinal disease.
BioAge said CFO Dov Goldstein and Chief Strategy Officer BJ Sullivan will take part in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4. One-on-one meetings with investors are also planned. The company said webcasts will be archived for 30 days.
BGE-102 is an NLRP3 inhibitor meant to target an inflammatory protein complex linked to age-related chronic inflammation, according to BioAge. The company is running it for cardiovascular risk and retinal diseases, such as diabetic macular edema, an eye problem tied to diabetes that can harm vision.
Next steps will be key. BioAge is aiming to kick off a Phase 2 dose-ranging proof-of-concept trial for cardiovascular risk in mid-2026. Data should land by the end of the year. The company describes a proof-of-concept trial as an early test to see if the drug works well enough in patients to warrant bigger studies. A Phase 1b/2a trial in diabetic macular edema is also slated for mid-2026, with a readout expected by mid-2027.
BioAge reported in April that its Phase 1 data showed at least 85% median drops in high-sensitivity C-reactive protein, or hsCRP, at both 60 mg and 120 mg once a day. hsCRP is a blood marker used to track inflammation tied to cardiovascular risk. The company said BGE-102 was well tolerated at all dose levels, with no serious adverse events in the trial.
BioAge CEO and co-founder Kristen Fortney said this month the April data “reinforce our conviction” in BGE-102, and said, “Our focus now is execution.” In statements right after the earlier data, she described the drug as a possible “pipeline in a pill.” Investors will want to see if the company’s trial timelines back that up. BioAge Labs, Inc.
BioAge chief medical officer Paul Rubin called hsCRP “among the most predictive biomarkers” for cardiovascular risk and said a tolerable oral drug could see wide use in prevention. That remains BioAge’s stance. Future trials still have to prove the biomarker effect in the settings the company targets. GlobeNewswire
BioAge reported it finished March with $384.9 million in cash, cash equivalents and marketable securities, and expects that to cover operations and capital spending into 2029. Collaboration revenue for the first quarter was $2.8 million, up from $1.5 million a year ago. R&D spending climbed to $20.4 million and net loss was wider at $22.3 million.
BioAge has analysts looking again after the BGE-102 update. This week, Insider Monkey said BTIG started coverage with a Buy and a $40 target, citing cash on hand and trial milestones coming up. Jefferies’ Roger Song, quoted in March by Investing.com, called BGE-102 best-in-class and pointed out the company’s cash should last until 2029.
The race in NLRP3 just picked up. In January, Eli Lilly agreed to buy Ventyx Biosciences for $1.2 billion, putting a new valuation on the space. Lilly said Ventyx brings small-molecule drugs aimed at inflammatory disease, including NLRP3 inhibitors. Reuters reported that a Ventyx drug in mid-stage trials is for a heart condition tied to obesity.
Downside risk is clear here. BioAge in its last quarterly filing said it hasn’t finished any clinical trials past Phase 1b and doesn’t have approved commercial products. The company also flagged that drug studies could fail on safety or efficacy, run over budget, or get held up in enrollment or completion. Any safety issue, trial delay, or bad patient data could hit the stock even with the cash on hand.
Nasdaq will be closed Monday, May 25, for Memorial Day. Trading pauses after the long weekend. BioAge’s next shot on the market won’t come until after its June investor update, when the company will have to reassure watchers that 2026 trial starts are still in sight.
